Laboratory technique to multiply a DNA sample for study
POPULARITY
Categories
63 episodes with pcr
24 episodes with pcr
43 episodes with pcr
19 episodes with pcr
49 episodes with pcr
21 episodes with pcr
31 episodes with pcr
18 episodes with pcr
37 episodes with pcr
12 episodes with pcr
16 episodes with pcr
21 episodes with pcr
14 episodes with pcr
10 episodes with pcr
15 episodes with pcr
13 episodes with pcr
14 episodes with pcr
9 episodes with pcr
10 episodes with pcr
8 episodes with pcr
8 episodes with pcr
12 episodes with pcr
12 episodes with pcr
16 episodes with pcr
10 episodes with pcr
20 episodes with pcr
20 episodes with pcr
20 episodes with pcr
20 episodes with pcr
13 episodes with pcr
12 episodes with pcr
13 episodes with pcr
19 episodes with pcr
19 episodes with pcr
10 episodes with pcr
18 episodes with pcr
18 episodes with pcr
10 episodes with pcr
13 episodes with pcr
13 episodes with pcr
8 episodes with pcr
8 episodes with pcr
9 episodes with pcr
10 episodes with pcr
10 episodes with pcr
8 episodes with pcr
12 episodes with pcr
8 episodes with pcr
13 episodes with pcr
4 episodes with pcr
4 episodes with pcr
7 episodes with pcr
8 episodes with pcr
9 episodes with pcr
4 episodes with pcr
4 episodes with pcr
8 episodes with pcr
7 episodes with pcr
7 episodes with pcr
9 episodes with pcr
10 episodes with pcr
13 episodes with pcr
6 episodes with pcr
7 episodes with pcr
10 episodes with pcr
8 episodes with pcr
7 episodes with pcr
12 episodes with pcr
12 episodes with pcr
7 episodes with pcr
6 episodes with pcr
7 episodes with pcr
7 episodes with pcr
11 episodes with pcr
6 episodes with pcr
7 episodes with pcr
5 episodes with pcr
3 episodes with pcr
5 episodes with pcr
9 episodes with pcr
5 episodes with pcr
6 episodes with pcr
6 episodes with pcr
6 episodes with pcr
6 episodes with pcr
3 episodes with pcr
7 episodes with pcr
4 episodes with pcr
9 episodes with pcr
4 episodes with pcr
4 episodes with pcr
7 episodes with pcr
6 episodes with pcr
4 episodes with pcr
4 episodes with pcr
6 episodes with pcr
9 episodes with pcr
5 episodes with pcr
4 episodes with pcr
5 episodes with pcr
5 episodes with pcr
5 episodes with pcr
5 episodes with pcr
5 episodes with pcr
3 episodes with pcr
5 episodes with pcr
3 episodes with pcr
3 episodes with pcr
4 episodes with pcr
3 episodes with pcr
8 episodes with pcr
6 episodes with pcr
12 episodes with pcr
7 episodes with pcr
2 episodes with pcr
4 episodes with pcr
3 episodes with pcr
5 episodes with pcr
2 episodes with pcr
5 episodes with pcr
4 episodes with pcr
4 episodes with pcr
4 episodes with pcr
3 episodes with pcr
5 episodes with pcr
5 episodes with pcr
4 episodes with pcr
2 episodes with pcr
3 episodes with pcr
3 episodes with pcr
2 episodes with pcr
6 episodes with pcr
5 episodes with pcr
2 episodes with pcr
3 episodes with pcr
7 episodes with pcr
7 episodes with pcr
7 episodes with pcr
2 episodes with pcr
4 episodes with pcr
4 episodes with pcr
3 episodes with pcr
4 episodes with pcr
2 episodes with pcr
4 episodes with pcr
3 episodes with pcr
3 episodes with pcr
4 episodes with pcr
4 episodes with pcr
3 episodes with pcr
3 episodes with pcr
3 episodes with pcr
5 episodes with pcr
5 episodes with pcr
4 episodes with pcr
4 episodes with pcr
3 episodes with pcr
4 episodes with pcr
2 episodes with pcr
3 episodes with pcr
4 episodes with pcr
4 episodes with pcr
3 episodes with pcr
4 episodes with pcr
4 episodes with pcr
3 episodes with pcr
2 episodes with pcr
2 episodes with pcr
4 episodes with pcr
5 episodes with pcr
4 episodes with pcr
The 2020's have so far been a decade of abundance and progress for society's awareness and understanding of Indoor Air Quality (IAQ). Beyond and before the pandemic put IAQ on everyone's mind, researchers have been enjoying well funded support from various organizations, both public and private, to better understand the impacts of indoor air on our health and well being. Plus cutting edge technologies from novel mass spectrometers to real-time PCR and next-generation DNA sequencing are both expanding and accelerating our understanding of the richness, diversity and significance of indoor air quality in our lives. Join us for this engaging and somewhat nerdy discussion with Dr Pawel Misztal, an assistant professor from the University of Texas at Austin's Civil Architectural and Environmental Engineering department. In this conversation Pawel unpacks the story of indoor air emissions and their impact on us. The emissions come from many sources including what we do, who we are (our bodies are highly active emission sources), and the microbes that live on every surface indoors.———-TeamHosted by Kristof IrwinProduced by M. WalkerEdited by Nico Mignardi
Monica Smit is Australia's first political prisoner. In 2021, she was arrested and spent 22 days in solitary confinement for 'crimes' including encouraging people to protest against Victoria state premier Dan Andrews's draconian lockdown/vaccine policies and refusing to take a PCR test. She is the founder of activist group Reignite Democracy Australia. For more details about her tour, her new book ‘Cell 22', her merchandise and her campaigns go to her website http://www.MonicaSmit.com ↓ ↓ ↓ If you need silver and gold bullion - and who wouldn't in these dark times? - then the place to go is The Pure Gold Company. Either they can deliver worldwide to your door - or store it for you in vaults in London and Zurich. You even use it for your pension. Cash out of gold whenever you like: liquidate within 24 hours. https://bit.ly/James-Delingpole-Gold / / / / / / Earn interest on Gold: https://monetary-metals.com/delingpole/ / / / / / / Buy James a Coffee at: https://www.buymeacoffee.com/jamesdelingpole Support James' Writing at: https://delingpole.substack.com Support James monthly at: https://locals.com/member/JamesDelingpole?community_id=7720
Monica Smit is Australia’s first political prisoner. In 2021, she was arrested and spent 22 days in solitary confinement for ‘crimes’ including encouraging people to protest against Victoria state premier Dan Andrews’s draconian lockdown/vaccine policies and refusing to take a PCR test. She is the founder of activist group Reignite Democracy Australia. For more details […]
#STSNation, Welcome to another episode of Surviving The Survivor, the podcast that brings you the #BestGuests in all of #TrueCrime… Convicted killer and disgraced lawyer Alex Murdaugh wants a new trial over the murders of his wife and younger son, filing court papers that accuse the clerk of court in Colleton County, S.C., of tampering with the jury who found him guilty. #BestGuests: Eric Bland was selected for inclusion in the South Carolina Super Lawyers in the 2015, 2016 and 2017 list for excellence and recognition as a Super Lawyer in Professional Liability. He was one of two in the entire State of South Carolina with this honor. He also happens to be representing Gloria' Satterfields family, the Murdaugh's housekeeper who died after a fall down a flight of stairs. He is host of Cup of Justice, a true crime podcast. Jonna Spilbor, Esq. is a popular and outspoken attorney, columnist, and legal analyst appearing regularly on the Fox News Channel, the Fox Business Network, and other television networks. She is the resident legal expert taking questions (and having fun) every Thursday morning on the number one morning radio show in New York's Hudson Valley-WPDH, 101.5 FM. Jonna also co-hosts, the award-winning radio show, "Happy Hour with Jonna & Keryl" which airs weekly on K104.7 FM; a member of the Pamal broadcasting group. Jonna frequently lends her legal voice to other television projects, including the Law and Crime Network, E! Entertainment Television and Oxygen (appearing on Killer Posts, Killer Couples and other murder mystery docu-dramas). Aimee Zmroczek is the owner of A.J.Z. Law Firm, LLC. focusing on criminal defense, PCR's, and Plaintiff's cases in both state and federal courts. She's been voted as a member of superlawyers continuously since 2019 and have had over 10 not guilty's on felony cases (murder, rape) since 2009 Amy Lawrence fights for the civil rights of the wrongfully accused every day in her practice at The Lovely Law Firm. Amy was on MTV's Teen Mom 2 and has appeared on the Dr. Phil show.
This is the first part of a trilogy that I made for Pax Palestine Podcast about the 'Civil Society for Dignity' project, a project by MEND, PCR, PCPD and PAX for Peace, supported by the European Union. This project aims to bridge the gap between the Palestinian civil society and the local governments.In this first episode you will learn more about the political reality for Palestinians under military rule and the civil society landscape of Palestine, in an interview with George Rishmawi, Director of the Palestinian Center for Rapprochement of people.Partners in this joined project are:MEND stands for Middle East Non Violence and Democracy. MEND promotes active nonviolence and encourages alternatives to violence among youth and adults throughout Palestine. MEND employs innovative methods, especially with the media, and is widely respected for working with authenticity, professionalism and courage.PCR is the Palestinian Center for Rapprochement between people. PCR works to bridge the gap between Palestinians and peoples from all around the world, informing the public about the reality in Palestine, and empowering the community through nonviolent direct action. PCPD is the Palestinian Center for Peace and Democracy. They were established to promote a just peace based on the Palestinian Declaration of Independence of 1988 and relevant United Nations Resolutions towards a two state solution, in which democracy and social justice are guaranteed. PAX for Peace is based in the Netherlands and works together with committed citizens and partners to protect civilians against acts of war, to end armed violence, and to build a just peace. In Palestine PAX supports local partners in building resilient communities, promoting human security and equality in the political, cultural and social domain, and in fighting the injustices resulting from the protracted occupation. If you want to know more about the work of Pax for Peace you can visit their website https://paxforpeace.nlMEND: https://www.mend-online.org/PCR: https://www.pcr.ps PCPD: https://pcpd.ps
This is the second part of a trilogy I made for Pax Palestine Podcast about the 'Civil Society for Dignity' project, a project by MEND, PCR, PCPD and PAX for Peace, supported by the European Union. This project aims to bridge the gap between the Palestinian civil society and the local governments.In this episode you will learn more about the project 'Civil Society for Dignity' itself. Muna Rishmawi, the project manager, talks about the aims of the project, the cooperation between the different organizations that are involved and how the project is being implemented. One of the young female participants, Aseel, tells us about her personal experiences and what her participation meant to her personal development. We conclude with Yara, who carried out a research and shares her findings with us. Partners in this joined project are:MEND stands for Middle East Non Violence and Democracy. MEND promotes active nonviolence and encourages alternatives to violence among youth and adults throughout Palestine. MEND employs innovative methods, especially with the media, and is widely respected for working with authenticity, professionalism and courage.PCR is the Palestinian Center for Rapprochement between people. PCR works to bridge the gap between Palestinians and peoples from all around the world, informing the public about the reality in Palestine, and empowering the community through nonviolent direct action. PCPD is the Palestinian Center for Peace and Democracy. They were established to promote a just peace based on the Palestinian Declaration of Independence of 1988 and relevant United Nations Resolutions towards a two state solution, in which democracy and social justice are guaranteed. PAX for Peace is based in the Netherlands and works together with committed citizens and partners to protect civilians against acts of war, to end armed violence, and to build a just peace. In Palestine PAX supports local partners in building resilient communities, promoting human security and equality in the political, cultural and social domain, and in fighting the injustices resulting from the protracted occupation. If you want to know more about the work of Pax for Peace you can visit their website https://paxforpeace.nlMEND: https://www.mend-online.org/PCR: https://www.pcr.ps PCPD: https://pcpd.ps
This is the third and last part of a trilogy that I made for Pax Palestine Podcast about the 'Civil Society for Dignity' project, a project by MEND, PCR, PCPD and PAX for Peace, supported by the European Union. This project aims to bridge the gap between the Palestinian civil society and the local governments.In this last episode Anwaar, who works for MEND and is the media and outreach coordinator for this project and journalist Hayat Hamdan tell us more about an important part of the Civil Society for Dignity project: the media training. This training helps young Palestinians to brainstorm about and to vocalize what they would like to change in their societies and it teaches them the skills and tools to create media content that can be used to communicate their wishes for change. This is an important skill that can be used in civil society participation on the political level. Partners in this joined project are:MEND stands for Middle East Non Violence and Democracy. MEND promotes active nonviolence and encourages alternatives to violence among youth and adults throughout Palestine. MEND employs innovative methods, especially with the media, and is widely respected for working with authenticity, professionalism and courage.PCR is the Palestinian Center for Rapprochement between people. PCR works to bridge the gap between Palestinians and peoples from all around the world, informing the public about the reality in Palestine, and empowering the community through nonviolent direct action. PCPD is the Palestinian Center for Peace and Democracy. They were established to promote a just peace based on the Palestinian Declaration of Independence of 1988 and relevant United Nations Resolutions towards a two state solution, in which democracy and social justice are guaranteed. PAX for Peace is based in the Netherlands and works together with committed citizens and partners to protect civilians against acts of war, to end armed violence, and to build a just peace. In Palestine PAX supports local partners in building resilient communities, promoting human security and equality in the political, cultural and social domain, and in fighting the injustices resulting from the protracted occupation. If you want to know more about the work of Pax for Peace you can visit their website https://paxforpeace.nlMEND: https://www.mend-online.org/PCR: https://www.pcr.ps PCPD: https://pcpd.ps
BrownTown is delighted to -- for the first time -- share a new series from our movement media fam over at AirGo. Help This Garden Grow is a new six-part podcast documentary series telling the story of Hazel Johnson, a visionary of the Environmental Justice movement and a resident of the Altgeld Gardens community on the far South Side of Chicago. Hazel is the founder of People for Community Recovery, a 40 year-old organization that fights to address the toxic industrial pollution that has been killing the members of her community. Over the course of the multigenerational multipart documentary, hosts Damon Williams and Daniel Kisslinger talk with organizers, policy-makers, historians, and community members about how PCR emerged and led, the legacy of Ms. Johnson's work, and how this marginalized Chicago pocket built the lineage of today's vibrant, impactful, and necessary modern environmental justice movement. Help This Garden Grow is presented by Respair Production & Media, Elevate, and People for Community Recovery. Subscribe by searching Help This Garden Grow wherever you get your podcasts (Apple, Spotify), check out respairmedia.com for more info, and support the work of People for Community Recovery!--Be on the lookout for future screenings of One Million Experiments and new episodes from Bourbon 'n BrownTown including our 100th episode! CREDITS: Intro audio mixing by Kiera Battles. Episode music credits: Contact by Anitek, Sunrise Drive by South Londo HiFi, Intelligent Galaxy by The Insider, Roy by Blanked, Spilled Beans by Gurty Beats, Life Is by Cosimo Fogg, Merry Bay by Ghostwriter Official, Catch My Breath by Ambient Boy, Be Quiet by Jahzzar, Ashes by AANI - produced by Adlai, mixing/mastering by Nicky Young.--Bourbon 'n BrownTownFacebook | Twitter | Instagram | Site | Linktree | PatreonSoapBox Productions and Organizing, 501(c)3Facebook | Twitter | Instagram | Site | Linktree | Support
Dennis Prager says liberals don't know what they're doing when they vote for leftists. True. But he's blind to the same problem on the right Political cartoonish Michael Ramirez, free market & conservative, responds to those who think he's changed because he occasionally does a critical cartoon of Trump. Will Trump hand the country to Democrats? He makes a compelling argument Trump's tariff plan would put a 10% tax on ALL imports. An additional $2 Trillion in taxes. A feature or a bug? WATCH: Trump's Moment of Truth about Fauci — Megyn Kelly nails him on how he put Fauci in charge and Trump responds with an unbelievable LIE Musk's "X" censors man who called for justice for Fauci As abortionists file lawsuits in 3 states to allow abortions, this mother chose to forgo an abortion and delayed treatment for rapidly advancing cancer, the baby is now a year oldINTERVIEW Federal Reserve is LOSING MONEY The Federal Reserve creates money, but they're LOSING money themselves …so why would you trust their fiat currency? Also, Argentina's hyperinflation, poverty, and questions about precious metal IRAs. Tony Arterburn, DavidKnight.gold, joins. INTERVIEW Andrew Kaufman, MD - Real Virus or Computer Model? The pandemic is not based on science, but circular logic about contagious disease, viruses, and vaccines. Dr. Andrew Kaufman MD, AndrewKaufmanMD.com, joins to talk about the assumptions inherent in the computer models, PCR tests, and variants used to control the publicFind out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Money is only what YOU hold: Go to DavidKnight.gold for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to TrendsJournal.com and enter the code KNIGHT
The pandemic is not based on science, but circular logic about contagious disease, viruses, and vaccines.Dr. Andrew Kaufman MD, AndrewKaufmanMD.com, joins to talk about the assumptions inherent in the computer models, PCR tests, and variants used to control the publicFind out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Money is only what YOU hold: Go to DavidKnight.gold for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to TrendsJournal.com and enter the code KNIGHT
Dennis Prager says liberals don't know what they're doing when they vote for leftists. True. But he's blind to the same problem on the rightPolitical cartoonish Michael Ramirez, free market & conservative, responds to those who think he's changed because he occasionally does a critical cartoon of Trump. Will Trump hand the country to Democrats? He makes a compelling argumentTrump's tariff plan would put a 10% tax on ALL imports. An additional $2 Trillion in taxes. A feature or a bug?WATCH: Trump's Moment of Truth about Fauci — Megyn Kelly nails him on how he put Fauci in charge and Trump responds with an unbelievable LIEMusk's "X" censors man who called for justice for FauciAs abortionists file lawsuits in 3 states to allow abortions, this mother chose to forgo an abortion and delayed treatment for rapidly advancing cancer, the baby is now a year oldINTERVIEW Federal Reserve is LOSING MONEY The Federal Reserve creates money, but they're LOSING money themselves …so why would you trust their fiat currency? Also, Argentina's hyperinflation, poverty, and questions about precious metal IRAs. Tony Arterburn, DavidKnight.gold, joins. INTERVIEW Andrew Kaufman, MD - Real Virus or Computer Model? The pandemic is not based on science, but circular logic about contagious disease, viruses, and vaccines. Dr. Andrew Kaufman MD, AndrewKaufmanMD.com, joins to talk about the assumptions inherent in the computer models, PCR tests, and variants used to control the publicFind out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Money is only what YOU hold: Go to DavidKnight.gold for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to TrendsJournal.com and enter the code KNIGHT
The pandemic is not based on science, but circular logic about contagious disease, viruses, and vaccines.Dr. Andrew Kaufman MD, AndrewKaufmanMD.com, joins to talk about the assumptions inherent in the computer models, PCR tests, and variants used to control the publicFind out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Money is only what YOU hold: Go to DavidKnight.gold for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to TrendsJournal.com and enter the code KNIGHT
On this episode, Jared has a very special guest, Dr. Meryl Nass. Dr. Nass is an internal medicine physician and was the first person in the world to prove that an epidemic was due to biological warfare. She has given 6 Congressional testimonies regarding anthrax, biological warfare, Gulf War syndrome and vaccine safety, and has consulted for the Cuban Ministry of Health, the World Bank and the Director of National Intelligence. Her medical license was suspended in January of 2022 for providing early COVID treatment and spreading so called “vaccine misinformation”. She has been writing and speaking on all things COVID, and now on the Biosecurity Agenda of the W.H.O. and its goal to wrest sovereignty from individual nations under the guise of a pandemic response. She will be speaking alongside Jared at the 2023 Your Health Freedom Symposium in October and if you've never heard her speak before, we are happy to introduce you to Dr. Meryl Nass on Vitality Radio.Additional Information:Door To FreedomDr. Meryl Nass SubstackThe WHO's Proposed Treaty - articleDr. Nass' International Covid Summit PresentationYour Health Freedom SymposiumVisit the podcast website here: VitalityRadio.comYou can follow @vitalityradio and @vitalitynutritionbountiful on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Please also join us on the Dearly Discarded Podcast with Jared St. Clair.Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.
September 8, 2023 Ray, Mark, and Scott discuss questions that came into the Urology Coding and Reimbursement Group:We use shared visits to facilitate our inpatient consultations. Typically our APP will perform history and exam, and the physician will perform the elements of the MDM. Our coders are having a controversy as to if this is acceptable for using FS modifier stating shared visits have to be based on time and feel should be billed as the APP doing the substantive work. Our understanding is that those changes (time based only) were delayed until 2024, so for remaining 2023 the physician can continue to be the billing provider as long as we are doing the MDM element as the “substantive portion.”Any further clarification available?(Also In that scenario, would it be conceivable to be the billing provider even in the absence face to fave encounter if the elements of MDM are met. Thoughts?)Does anyone know where to find "Procedure to Provider" edits? We have a PCR lab in Illinois and two of the billed codes are being denied with CO B7 reason code. This reason code indicates the provider is not eligible forUrology Documentation, Coding, and Billing CertificationFor Urologists and APPs (Click Here for Pricing, More Information, and Registration)Documentation, Coding, and Billing Fellowship - Urology (DCB-FS) For Coders, Billers, and Admins (Click Here for Pricing, More Information, and Registration)Documentation, Coding, and Billing Specialist Certification (DCB-SC)Documentation, Coding, and Billing Master Certification (DCB-MC)Urology Advanced Coding and Reimbursement Seminar(Click Here for More information and Registration) Las Vegas, December 1 & 2, 20238 am - 4:30 pm Friday, 8 am - 3:30 pm SaturdayNew Orleans, January 26 & 27, 20248 am - 4:30 pm Friday, 8 am - 3:30 pm SaturdayReserve your spot and save!As a Urology Coding and Reimbursement Podcast listener, you get access to a discount (expires 8/31/23).Use code: 24UACRS733Get signed up today and get peace of mind knowing you will be prepared for all the upcoming changes.The Thriving Urology Practice Facebook group.The Thriving Urology Practice Facebook Group link to join:https://www.facebook.com/groups/ThrivingPractice/ Join the discussion:Urology Coding and Reimbursement Group - Join for free and ask your questions, and share your wisdom.Click Here to Start Your Free Trial of AUACodingToday.com
Interview with Klaire and Alex of GUJI 咕叽, EP of GUJI 咕叽, a quirky synth-driven new wave quartet comprised of Chinese nationals Klaire (synths), Alex (bass), Stacy (drum machine) and American guitarist and singer for Shanghai punk band Round Eye Chachy with an interview. The EP will be released in late Summer August 25 by Floridian label Godless America. The EP was produced by frequent Modern Sky Recordings producer Li Wei Yu To say 2020-2022 were bleak years to live in Shanghai would be the understatement of the century. With the implementation of the “0-Covid policy” and the “Shanghai Lockdown”, a fucked attempt by the CCP to curb the transmission rate of the Covid-19 pandemic, the city became still. Businesses shuttered, schools closed, planes landed, shows cancelled and borders closed. For three years, China seemed without pulse as very little traffic ran between it and the outside world. Guizhou native Jiang Zi Xiu (Klaire) and Craig Englund (Chachy) were stuck in their home for months as a makeshift wall of plywood and bamboo rods was raised at the entrance and exits of the alleyway outside their door. Guards in hazmat suits were placed to conduct daily PCR tests and make sure no one came in or out. It was under these conditions that the couple decided to fill their time and their walls with the double lead harmonies, jangling B-52 styled guitar and cheesy drum machine pulse of the sardonic bubblegum-arpeggiated synthpop of GUJI咕叽. Heavily influenced by the aesthetic of 80s DEVO, B-52s, and My Little Pony the duo channels their frustrations and observations into vivid DIY videos channeling the work of Chuck Statler and blast humorously sardonic synthpop jams lined with pastel colored neon lights. With their first self-titled EP, they turn their anger into childish jeering fun in an overwhelmingly hostile political landscape and with songs like “I like to Hang Out in China” and “My Mao Suit” the band waves at the outside world with hammer and sickle and dares those who listen to not strip and dance in the hot pink fire.
We're discussing the importance and the power of PCR testing for your cattery. This is some of the best information for anyone who is experiencing symptoms in your cattery, and don't know where to go for help.
Mark McDonough, the CEO of ChromaCode, is leveraging high-definition PCR testing to overcome the limitations of conventional PCR to identify biomarkers of infectious diseases and cancer. While gene sequencing can provide valuable information, it requires more tissue, is expensive, and requires at least a week for analysis. Using HDPCR, ChromaCode has developed a lung cancer assay that looks at nine genes and 15 biomarkers, requiring less tissue, performed at a lower cost, and provides results quickly. This approach, built on a cloud-supported multiplexing platform, provides flexibility to explore other areas in oncology and transplants, looking at multiple targets per sample. Mark explains, "With PCR today, assays look at particular biomarkers on a gene-by-gene basis. So those can be effective in lung cancer, for example, if you know you're just looking for EGFR as a biomarker or if you're looking at KRAS or ALK, a different mutation. But the problem is it's not very comprehensive, and you need a lot of tissue. So, PCR falls short because it's limited in scalability and requires a lot of tissue." "Why this is important for the patient in terms of patient empowerment and lung cancer is when a patient gets their result back from ChromaCode and their provider using ChromaCode technology, they also are more than likely having an immunochemistry test called PD-L1 run. They're trying to determine if there is a targeted therapy, or is it best to put a patient on immunotherapy, or is there a combination of immunotherapy and chemo?" "Having all that answer back in one to two days, as opposed to knowing what you'll get back from immunochemistry in a day and then waiting two weeks for sequencing, can be very problematic. So, we feel like we're meeting that open opportunity where sequencing is too slow and too expensive, requiring too much tissue, and PCR just isn't comprehensive enough and is very much trial and error on a one-by-one basis with our technology." #ChromaCode #HDPCR #Diagnostics #ChromaCodeCloud #Genomics #LungCancer #GeneSequencing chromacode.com Download the transcript here
Mark McDonough, the CEO of ChromaCode, is leveraging high-definition PCR testing to overcome the limitations of conventional PCR to identify biomarkers of infectious diseases and cancer. While gene sequencing can provide valuable information, it requires more tissue, is expensive, and requires at least a week for analysis. Using HDPCR, ChromaCode has developed a lung cancer assay that looks at nine genes and 15 biomarkers, requiring less tissue, performed at a lower cost, and provides results quickly. This approach, built on a cloud-supported multiplexing platform, provides flexibility to explore other areas in oncology and transplants, looking at multiple targets per sample. Mark explains, "With PCR today, assays look at particular biomarkers on a gene-by-gene basis. So those can be effective in lung cancer, for example, if you know you're just looking for EGFR as a biomarker or if you're looking at KRAS or ALK, a different mutation. But the problem is it's not very comprehensive, and you need a lot of tissue. So, PCR falls short because it's limited in scalability and requires a lot of tissue." "Why this is important for the patient in terms of patient empowerment and lung cancer is when a patient gets their result back from ChromaCode and their provider using ChromaCode technology, they also are more than likely having an immunochemistry test called PD-L1 run. They're trying to determine if there is a targeted therapy, or is it best to put a patient on immunotherapy, or is there a combination of immunotherapy and chemo?" "Having all that answer back in one to two days, as opposed to knowing what you'll get back from immunochemistry in a day and then waiting two weeks for sequencing, can be very problematic. So, we feel like we're meeting that open opportunity where sequencing is too slow and too expensive, requiring too much tissue, and PCR just isn't comprehensive enough and is very much trial and error on a one-by-one basis with our technology." #ChromaCode #HDPCR #Diagnostics #ChromaCodeCloud #Genomics #LungCancer #GeneSequencing chromacode.com Listen to the podcast here
În acest episod vorbesc despre popularitatea și charisma lui Ion Iliescu, dar și despre anturajul său de oameni de încredere. Vorbesc despre afacerile deșănțate și țepele economice care au proliferat sub protecția statului și a relațiilor clientelare improprii: antreprenori ieșiți din Securitate sau din vechiul PCR, scandalul bancar, privatizările lente și preferențiale, schema piramidală Caritas și contrabanda. Însă apare la orizont și perspectiva alinierii internaționale, în foruri suprastatale. Progresele României în acest sens sunt încă mici și șovăielnice, dar începe acum angajarea pe o direcție occidentală. Încheierea unui tratat bilateral cu Ungaria îi supără pe naționaliști. Presiunea internă cauzată de presa independentă, de opoziție și de societatea civilă duce la rezultate diferite în alegerile din 1996. PDSR intră în opoziție, iar Ion Iliescu devine primul șef de stat al României care cedează puterea în mod pașnic.Support the show
I don't know about you, but one of my least favourite things to see on my consult list is a cat with a snotty nose. The idea that my patient's problem can be anything from a self-limiting mild disease to a serious and frustrating impossible-to-treat condition, and the decision-making around this, fills me with uncertainty and dread. This episode aims to replace that uncertainty with confidence, or at least a solid plan based on sound knowledge! Dr Kath Briscoe is a Specialist in Feline Medicine who has worked in academic and specialist referral centres and as a referral clinician in a GP setting, and her experience gives her a great insight into the frontline work that we deal with in a non-referral setting. Dr Megan Braunstein is a practice owner and practicing clinician with a Masters in Small Animal Medicine and Surgery and many years of experience. Her practice in Perth, Western Australia, submitted the most feline respiratory PCR panels of any practice on Australia last year, and she helps us unpack what they're learning about these tests. Between them, they'll refresh your foundational knowledge about infectious causes of feline upper respiratory disease and help with decision-making around diagnostics and treatment. We delve into what's new in the world of diagnostics with a review of feline respiratory disease PCR panels, including learning what it's great for, when to use it, and how to do it. This episode is supported by our friends at the SVS Pathology Network, which our Australian listeners will know better as Vetnostics, QML Vetnostics, ASAP Laboratory and Vetpath Laboratory Services. The SVS Pathology Network provides a wide range of infectious disease PCR tests, including a comprehensive panel for feline respiratory pathogens. Their PCR panels are designed for detecting Australian pathogens, and they have recently introduced additional pathogens on several of their PCR panels. Our guests provide a detailed guide on how to take samples for PCR in this conversation, but your state-based SVS Pathology Network laboratory customer care team are always happy to answer any questions. Topic list: 1. Feline upper respiratory diagnostics: who needs what? [00:00:00-00:05:00] 2. Discussion of different types of feline upper respiratory diseases [00:05:00-00:06:00] 3. Importance of husbandry and stress management in preventing feline upper respiratory diseases [00:16:00-00:31:00] 4. Hygiene practices for cat households and catteries [00:31:00-00:33:00] 5. Overview of infectious causes of feline upper respiratory diseases [00:02:00-00:08:00] 6. Discussion of feline herpesvirus and its symptoms [00:08:00-00:12:00] 7. Discussion of feline calicivirus and its symptoms [00:12:00-00:14:00] 8. Discussion of other infectious causes of feline upper respiratory diseases [00:14:00-00:16:00] 9. Vaccines for preventing feline upper respiratory diseases [00:16:00-00:18:00] 10. Overview of diagnostic tests for feline upper respiratory diseases [00:18:00-00:20:00] 11. Discussion of PCR panels and their usefulness in diagnosing feline upper respiratory diseases [00:20:00-00:22:00] 12. Discussion of treatment options for feline upper respiratory diseases [1, 00:24:00-00:28:00] Join our community of Vet Vault Nerds to lift your clinical game and get your groove back with our up to date easy-to-consume clinical episodes at vvn.supercast.com, visit thevetvault.com for the show notes and resources for this episode, and connect with us through our online Vet Vault Network. for episode highlights, discussions, questions and support. Subscribe to our weekly newsletter here. Come help us create some live clinical content at IVECSS '23 in Denver, Colorado from 7-11 September. Get up and running (or working!) with a 10% discount for Tarkine shoes, the official shoe of the Vet Vault. (discount automatically applied at checkout using this link). --- Send in a voice message: https://podcasters.spotify.com/pod/show/vet-vault/message
Scientists continuously develop new assays to fill unmet diagnostic needs. While methods such as quantitative PCR have emerged as essential tools in molecular diagnostics, scientists developing and administering these assays still must overcome technical challenges. In this podcast series, The Scientist's Creative Services Team talks to experts about their experiences designing and implementing assays and protocols for future molecular diagnostics. In this episode, Deanna MacNeil from The Scientist's Creative Services Team spoke with Ming-Sound Tsao, a senior scientist and clinician at Princess Margaret Cancer Centre, about considerations and variables for choosing appropriate assays in precision lung cancer treatment, including biomarkers, internal controls, test sensitivity, and specificity. Welcome to Molecular Diagnostics: An Eye Toward the Future, a special edition podcast series produced by The Scientist's Creative Services Team. This series is brought to you by Thermo Fisher Scientific, a world leader in serving science. Their mission is to enable customers to make the world healthier, cleaner, and safer. Whether their customers are accelerating life sciences research, solving complex analytical challenges, and improving clinical research workflows, Thermo Fisher Scientific is here to support them.
Dr. Paul Alexander Liberty Hour – 20 Horsemen of the COVID Apocalypse who IMO have caused death, direct or indirect, by their actions in COVID response and vaccine. Did we miss any malfeasant? Who do you want on tap? Let us debate and discuss. I mean all those linked to the mRNA gene injection too...all...from virus to release to gain-of-function research to PCR 'false-positive' process fake pandemic to vaccine. The 20 Horsemen...
COVID cases nationwide and in California are increasing at summer's end. The state's positivity rate from PCR tests is almost 12% as of mid-August, and wastewater data indicate that the new omicron subvariant, EG.5, is on the rise. But reported case rates are still far below peaks from last winter; UCSF's Dr. Peter Chin-Hong told the San Francisco Chronicle, “people should not be worried but should not tune out.” We'll learn more with Dr. Chin-Hong and hear about the new fall booster and the latest research into long COVID and take your COVID questions. Guests: Dr. Peter Chin-Hong M.D., infectious disease specialist, UCSF Medical Center
Dr. Jessica Rose is an artist, musician, mathematician, professional surfer, biologist, researcher, & data analysis. Dr. Rose has a Post Doc in Biochemistry at Technion Institute of Technology, Post Doc in Molecular Biology at Hebrew University of Jerusalem, PhD in Computational Biology at Bar Ilan University, Master's in Medicine (Immunology) at Memorial University of Newfoundland, and BSc in Applied Mathematics at Memorial University of Newfoundland.DR. JESSICA ROSEWebsite: https://www.jessicasuniverse.com/Twitter: https://twitter.com/JesslovesMJKSubStack: https://jessicar.substack.com/YouTube: https://www.youtube.com/channel/UC0EhWf2Vswdg7DwKKKZ34ngTHE RIPPLE EFFECT PODCAST:WEBSITE: http://TheRippleEffectPodcast.comWebsite Host & Video Distributor: https://ContentSafe.co/SUPPORT:PATREON: https://www.patreon.com/TheRippleEffectPodcastPayPal: https://www.PayPal.com/paypalme/RvTheory6VENMO: https://venmo.com/code?user_id=3625073915201071418&created=1663262894MERCH Store: http://www.TheRippleEffectPodcastMerch.comMUSIC: https://music.apple.com/us/album/the-ripple-effect-ep/1057436436SPONSORS:LMNT Electrolyte Drink Mix (Free Gift With Purchase): http://DrinkLMNT.com/TheRippleEffectNEW LMNT CHOCOLATE MEDLEY (Free Gift With Purchase): https://drinklmnt.com/pages/chocolate-medley?rfsn=6589695.aa3fa8&utm_medium=affiliate&utm_source=rickyvarandas&utm_campaign=chocolatemedley&utm_content=&utm_term=THE UNIVERSITY OF REASON (Autonomy Course): https://www.universityofreason.com/a/29887/ouiRXFoLContentSafe: https://ContentSafe.co/WATCH:ROKFIN: https://rokfin.com/RippleEffectODYSEE: https://odysee.com/@therippleeffectpodcast:dRUMBLE: https://rumble.com/c/c-745495YOUTUBE: https://www.youtube.com/channel/UCVfy9MXhb5EIciYRIO9cKUwLISTEN:SPOTIFY: https://open.spotify.com/show/4lpFhHI6CqdZKW0QDyOicJiTUNES: http://apple.co/1xjWmlFSUBSTACK: https://TheRippleEffectPodcast.substack.com/CONNECT:TeleGram: https://t.me/TREpodcastTWITTER: https://twitter.com/RvTheory6INSTAGRAM: https://www.instagram.com/rvtheory6/
The ability to extract DNA from ancient fragments of biological material has revolutionized our understanding of recent evolutionary history, including human evolution and phylogeography. Analysis of ancient DNA in tandem with radiocarbon dating, along with traditional archeological techniques, has led to a flurry of discoveries. With us to discuss this research is Maanasa Raghavan. Maanasa is a Neubauer Family Assistant Professor of Human Genetics at the University of Chicago.
In this episode, we are thrilled to be interviewing Professor Ed Breitschwerdt, a renowned expert in the field of Bartonella research, often a co-infection of Lyme disease. He is currently a professor of medicine and infectious disease at North Carolina State University and an adjunct professor of medicine at Duke University Medical Center. He has written 186 research studies with the word "Bartonella" in the title. Research Lab: His laboratory focuses on testing animals, especially companion animals like cats, dogs, and horses, for vector-transmitted infectious diseases, like Bartonella and Lyme disease. Through years of intensive research, Professor Breitschwerdt and his team have become the reference laboratory for these diseases in animals. An Expert in the Field: Professor Breitschwerdt also directs North Carolina State University's Intracellular Pathogens Research Laboratory in the Institute for Comparative Medicine, co-directs the Vector Borne Diseases Diagnostic Laboratory, and has co-supervised the Tick-transmitted Diagnostic Laboratory since 1984. He has also supervised a biosafety level P-3 research laboratory. The Focus on Bartonella: Currently, there are about 15 to 16 known species of Bartonella causing diseases in humans. The most common disease caused by Bartonella is endocarditis, a life-threatening infection of the heart. Bartonella and Schizoaffective Disorders: Professor Breitschwerdt has performed studies strongly suggesting a connection between Bartonella infections and psychosis, mood disorders, and Tourette's syndrome. A study found that almost all schizophrenia and schizoaffective disorder patients tested positive for Bartonella and had symptom relief once receiving proper treatment. Bartonella's Effect on the Microbiome and Immune System: Chronic infection with Bartonella can alter the normal microbiome of the intestinal tract, likely due to immunosuppression or the disruption of immune modulation. Different strains of Bartonella may also lead to different symptoms in the human body. Once Bartonella enters the host, it becomes predominantly intracellular, infecting many different types of cells. Role of Galaxy Diagnostics in Bartonella Research: Galaxy Diagnostics, where Professor Breitschwerdt is the Chief Scientific Officer, has played a significant role in progressing Bartonella research and testing. This organization uses insect growth media and digital PCR for cultivating and identifying Bartonella in blood tests. Galaxy Diagnostics has become one of the leading Bartonella testing labs in the world. Bartonella Transmission: Professor Breitschwerdt cited numerous studies he's performed which suggest Bartonella can be transmitted sexually, through blood transfusions, congenitally from mother to child, or through a variety of vectors like ticks, cats, and bats to human beings. The Importance of Animals in Understanding Bartonella: Studying the effects of Bartonella in animals can provide important insights into how it behaves in humans. In some instances, the same Bartonella species can cause different diseases in humans and animals, adding another layer of complexity to the research. Closing Thoughts: Though there are still many questions surrounding Bartonella, researchers like Professor Breitschwerdt are working tirelessly to deepen our understanding.
Get ready to be inspired by our extraordinary guest, Yesenia Collins. A pivotal figure in her school's BioBuilderClub, Yesenia takes us along on her captivating journey, from her initial introduction to synthetic biology to her innovative projects at Tyngsborough High School. Can you imagine the thrill of manipulating organisms to produce novel scents or even creating a world of vibrant microbial colors? Yesenia did just that in the Smell Lab and What a Colorful World Lab. Yet, it wasn't all smooth sailing - grappling with complex concepts like PCR and understanding plasmids posed significant challenges. But with unrelenting determination, she not only persevered with her first project but also embraced an additional venture.But what can this world of synthetic biology mean for career paths? For Yesenia, it's everything! Our discussion uncovers the profound influence the BioBuilder program has had on her future aspirations. Driven to major in biochemistry and pursue a career in pharmaceutical research, Yesenia credits much of her ambition to the experiences and knowledge gained through BioBuilder. And as a student ambassador for the program, she's not stopping there. Listen in as she shares her exciting plans for the upcoming year at Georgia Tech. So, buckle up and join us on this enlightening expedition through the world of synthetic biology, led by one of this field's promising young talents.Learn more about BioBuilder's programs for students, educators, and industry professionals here
This podcast features Prof. Gernot Bonkat (CH) and Dr. Kathrin Bausch (CH) discussing the addition of a new chapter on urogenital tuberculosis to the EAU Guidelines on urological infections.They explain that the lack of knowledge among urologists about tuberculosis, particularly genital tuberculosis, was a reason for adding the new chapter. Tuberculosis is an ancient bacterial disease affecting not only the lungs but also other organs, including the urogenital tract. Diagnosis of urogenital tuberculosis is often delayed due to the disease's mixed and non-specific symptoms, and people may mistake it for a urinary tract infection (UTI).Prof. Bonkat and Dr. Kathrin discuss diagnostic options specifically for bladder and kidney tuberculosis, such as urine investigations, microscopy, and PCR - which allows for faster diagnosis and resistance testing (but is not affordable for everyone). Treatment recommendations are also discussed, as well as taking a look into the future of vaccination possibilities, and drug resistance.Prof. Gernot Bonkat (CH) is chair of the EAU Guidelines urological infections panel and Dr. Kathrin Bausch (CH) is member of the same panel.
As her health begins to wain, Hazel passes the baton to her daughter Cheryl who guides PCR through the treacherous waters of attacks, blackballing, and disrespect. Show Notes Support the work of People for Community Recovery - https://www.peopleforcommunityrecovery.org/join-our-fight/donate Learn about Respair Production & Media - https://www.respairmedia.com/ Music Credits Contact by Anitek Mounsell Forts by Roger Plexico Cinematic Sentimental Lullaby Sketch - Celesta only version by Gregor Quendel Funk by Podington Bear Cooling by Audiobinger Be Quiet by Jahzzar Ashes by AANI - produced by Adlai, mixing/mastering by Nicky Young
The gut microbiome is a fascinating area of human health that we just started to better understand in the last two decades. With the arrival of PCR sequencing and advanced PCR techniques, we've been able to characterize the microbiome by looking at what organisms live there and how they vary by location and diet, as well as how the microbiome is influenced by things like exposure to antibiotics. We're beginning to understand the relationship between the microbiome and health, from how these bacteria influence human metabolism and immune system development to their association with autoimmune diseases. Although we've learned a great deal, there's still a lot for us to understand about our microbiome, including the relationship between our nervous system and the bacteria in our gut. In this episode, we'll explore what we know and what we have left to discover with our guest Jaime Belkind-Gerson, MD. Guest: Jaime Belkind-Gerson, MD, is a pediatric gastroenterologist at Children's Hospital Colorado. Dr. Belkind-Gerson is an expert in neurogastroenterology and gastrointestinal motility, and he's an associate professor of pediatrics at the University of Colorado School of Medicine. For more information on Children's Hospital Colorado, visit: childrenscolorado.org
A bioweapon like none other fakeotube.com/video/6122/a-bio… Controlled opposition Kary Mullis and the PCR fraud | Fakeologist.com fakeologist.com/blog/2023/07/1… Excess deaths with Senator Rennick – YouTube www.youtube.com/watch?v=UR1X9O… Saturday Emergency Broadcast: Dr. Rima Laibow Exposes Next Phase fakeotube.com/video/6116/satur… What is a Woman: Wrong Answers Only fakeotube.com/video/6117/what-… Matt Walsh What Is A Woman? Documentary (Reloaded) [June 2, 2023] rumble.com/v2rrobo-matt-walsh-… […]
On this Episode 372 of Health Solutions, Shawn & Janet Needham R. Ph. discuss vaccines, the cost of being born, and medical freedom with Kristen Woodruff. Why is it so expensive to have a baby today and is there a solution to lower costs? Resources mentioned: “Dissolving Illusions” book https://a.co/d/bLKr4oK 00:00 - Start 00:22 - Introduction 02:10 - Kristen's exemption & termination 07:40 - Religious discrimination lawsuit 08:30 - MRNA & PCR test advocacy 10:50 - Kristen's vaccine-injured child 15:24 - Vitamin K & circumcision 19:14 - Informed consent 21:20 - Bullied by doctors 25:29 - C-sections 28:39 - Erythromycin 31:50 - Standing up to Doctors 37:51 - Healthcare trends 45:03 - Vaccine injury 52:31 - Pollio & Covid vaccines 55:06 - Become your own advocate 57:57 - Contact Kristen Woodruff Episode Resources Facebook ~ https://www.facebook.com/kristen.woodruff.31 Instagram ~ https://instagram.com/awakenursemama EP 372: Kristen Woodruff Discussing Vaccines, the Cost of Being Born, and Medical Freedom ~ #nurse #nicu #baby #babies #believemothers #icalltheshots #nursesforinformedconsent #podcastshow #optimalhealth #healthfreedom #medicalcare #HealthCare #PriceTransparency #freemarket #Liberty #FitAfter50 #FitOver50 #fitover40 #fitafter40 #Boise #IdahoFalls #Tricities #SiouxFalls #Wenatchee #EducateAndEmpower #NeedhamHealthSolutions #TeamNeedham #ShawnNeedham #HealthSolutions #MosesLakeProfessionalPharmacy #MLRX #SickenedTheBook #ShawnNeedhamRPh #ThinkOutsideTheSystem #OptimalHealthMatters #ItsTime ~ *** #BenShapiro & #DaveRamsey Fans. Learn how to be in the driver's seat for your healthcare choices {not the system or doctors!}
Justin Trudeau has sided with gender ideology over Muslims in Canada's latest cultural battle. While Muslim families across the country have expressed concern about what kids are being taught in schools, Trudeau says they're actually being coopted by the “far right” and “American right wing.” True North's Andrew Lawton talks about parental rights with RightNow co-founded Alissa Golob. Also, a new essay in C2C Journal by researcher Gleb Lisikh reveals the two critical tools the government used in bolstering pandemic fears – overreliance on PCR tests and overreporting Covid deaths. Lisikh joins The Andrew Lawton Show to discuss the piece, which you can read here. Learn more about your ad choices. Visit megaphone.fm/adchoices
Sponsored by Olivia Gardenhttps://store.oliviagarden.com/pages/superhpInterview with Frédéric FekkaiProvence-born and Paris-trained, Frédéric Fekkai opened his first ground-breaking namesake salon atop New York's Bergdorf Goodman department store in 1989 and today has the most recognized and luxurious hair salons in New York. During this time, he quickly became known for creating hairstyles on the catwalk, magazine covers and red carpets for notable supermodels and celebrities. In 1995, Frédéric created the prestige hair category with the launch of his product line, raising the industry standard from commodity to luxury by incorporating high performance ingredients found in prestige skincare, further enhanced by partnerships with the world's leading fragrance formulators. FEKKAI was acquired in 2006 by Procter & Gamble.Now, with a powerhouse standalone salon in Soho and an iconic salon within The Mark Hotel on the Upper East Side, Frédéric Fekkai has reclaimed his namesake brand, and re-launched FEKKAI with a new mission. He has created a high performance, clean collection of haircare that shatters the myths that clean products are less performative. With the brand's commitment to eliminate plastic waste by using high percentages of PCR in their recyclable bottles and tubes, and the latest product innovations, with three earth friendly, non-ozone depleting aerosols powered with Solstice® Propellant technology, he has sought out to do just that. Links: https://fekkai.com/?gclid=Cj0KCQjw756lBhDMARIsAEI0AglOq1wkY5bn1bXuwll6a57kefQu2iBYVC2oln4_GW7izZcYGzSItasaAgvsEALw_wcBhttps://www.instagram.com/fredericfekkai/?hl=enhttps://www.instagram.com/fekkai/?hl=enRant News:Everyone deserves relationships free from domestic violence. If someone is hurting you or someone you know, there is help. You can contact the National Domestic Violence Hotline at thehotline.org, or text the Crisis Text Line at 741-741.https://spectrumnews1.com/ma/worcester/news/2023/07/07/massachusetts-proposes-law-that-would-require-hair-care-facilities-to-take-domestic-violence-awareness-training-courseNews from TheTease.comhttps://www.thetease.com/celebrity-hairstylist-johnny-wright-will-be-touching-crowns-and-hearts-on-his-multi-city-naturally-you-tour/https://www.thetease.com/colorist-jacob-schwartz-shares-exactly-how-to-get-margot-robbies-barbie-blonde-hair-color-from-the-barbie-premiere/
Welcome to today's episode, where we plunge into the cutting-edge world of precision health testing with Genova Diagnostics. Join me as I share my personal experience and results from the Metabolomix+ and GI Effects tests, both renowned for their insights far surpassing those of conventional blood tests. They are also tests I require of each of my VIP coaching clients. The Metabolomix+ is an all-inclusive nutritional test offering analysis of critical nutritional biomarkers. This test uses a simple first-morning void (FMV) urine collection and provides an optional add-on bloodspot finger stick and buccal swab for assessment. It effectively identifies your functional need for antioxidants, B vitamins, minerals, digestive support, fatty acids, and amino acids, enabling incredibly targeted nutritional therapies. Next up is the GI Effects test. This is your go-to for a complete assessment of gut health. It's designed to uncover the root cause of most GI complaints using a combination of PCR, culture, and microscopic testing methods. The test ensures the identification of all relevant organisms, from yeast and parasites to markers of gut inflammation and bacterial imbalances. Both these tests are the creation of Genova Diagnostics, a leading clinical laboratory renowned for its work in diagnosing, treating, and preventing complex chronic diseases. They offer specialized testing services in gut health, nutritional status, immune function, hormonal health, and specialty testing. Most recently, they've launched Genova Connect aimed at athletes, high performers, and fitness enthusiasts. Joining me for this enlightening conversation are three esteemed members of the Genova team: Meet Jeffrey Ledford, Patricia Devers, and Michael Chapman, who bring a wealth of experience and innovation to the table. Full Show Notes: https://bengreenfieldlife.com/gdxpodcast Episode Sponsors: Alitura: Transform your skincare routine and unlock radiant, healthy skin with Alitura. Visit alitura.com today, use code BG20, and enjoy an exclusive 20% discount on your order. Cymbiotika: Elevate your health and wellness with Cymbiotika's scientifically proven health supplements. Use code BEN on cymbiotika.com for 15% off sitewide plus free shipping. ZBiotics: The world's first genetically engineered probiotic that helps break down the toxic byproduct of alcohol, Zbiotics allows you to enjoy your night out and feel great the next day. 100% money-back guarantee and 15% off your first order at zbiotics.com/BEN when you use code BEN. Bubs Naturals: Ready for a discount on the highest quality MCT oil powder, collagen protein, apple cider vinegar gummies, and more? Use code BENG for 20% off at bubsnaturals.com. JoyMode: Want to boost your sexual performance? And do it naturally without nasty prescription drugs? Visit usejoymode.com/GREENFIELD or enter GREENFIELD at checkout for 20% off.See omnystudio.com/listener for privacy information.
The topic of intestinal parasites and their prevalence is hotly debated in functional medicine. Furthermore, the increasing trend of people performing a ‘parasite cleanse' of the GI tract can be dangerous. Parasites are diagnosed in the stool using microscopy, direct exam, and PCR – but even then, not all parasites should be treated. Some can cause significant illness, yet others are not invasive, self-limiting, and considered nonpathogenic. In today's episode, we give a refresher course on gut parasites, discuss different ways to assess them, and introduce the topic of nonpathogenic parasites that don't need to be treated. Today on The Lab Report: 3:50 Prevalence and transmission of parasites 6:45 What is a parasite? Are there nonpathogenic parasites? 8:10 3 main classes of parasites 10:20 Detecting parasites in the stool 13:10 Nonpathogenic parasites Chilomastix mesnili, Endolimax nana, Entamoeba coli, Entamoeba dispar, Entamoeba hartmanni, Entamoeba polecki, Iodamoeba buetschlii 16:50 Potentially pathogenic parasites 19:25 Question of the Day Why doesn't Genova offer sensitivities for parasites on the GI Effects? Additional Resources: GI Effects Stool Profile Subscribe, Rate, & Review The Lab Report Thanks for tuning in to this week's episode of The Lab Report, presented by Genova Diagnostics, with your hosts Michael Chapman and Patti Devers. If you enjoyed this episode, please hit the subscribe button and give us a rating or leave a review. Don't forget to visit our website, like us on Facebook, follow us on Twitter, Instagram, and LinkedIn. Email Patti and Michael with your most interesting and pressing questions on functional medicine: podcast@gdx.net. And, be sure to share your favorite Lab Report episodes with your friends and colleagues on social media to help others learn more about Genova and all things related to functional medicine and specialty lab testing. To find a qualified healthcare provider to connect you with Genova testing, or to access select products directly yourself, visit Genova Connect. Disclaimer: The content and information shared in The Lab Report is for educational purposes only and should not be taken as medical advice. The views and opinions expressed in The Lab Report represent the opinions and views of Michael Chapman and Patti Devers and their guests. See omnystudio.com/listener for privacy information.
In this episode of Life Science Success my guests are Rahul Sharma, the co-founder and CSO of Scienetix, a company dedicated to enabling Molecular Diagnosis. Dr. Sharma is a board-certified laboratory director and technical lead for Next Generation Sequencing (NGS) and PCR-based assay development and clinical testing. He has developed multiple Molecular Diagnosis tests and translated them into clinical testing. Additionally, We are joined by Rob Carpenter PhD, MBA the CEO of Scienetix. Rob is a healthcare executive and educator with over 25 years' experience in developing, managing, and assimilating healthcare companies. He is distinctly skilled in business development and various business growth strategies. He is founder and current CEO of Advanta Genetics, a highly complex clinical and research laboratory accredited by the College of American Pathologists with concentration in infectious disease molecular genomics and Scienetix, a bioscientific company centered around products to optimize molecular genomic workflows. In the podcast, Dr. Sharma and Dr. Carpenter talk about the healthcare industry's need to optimize workflow and reduce costs in laboratory testing. Their company, Scienetix, is working on developing extraction-free tests that will eliminate the need for sample pre-processing and make testing more accessible and cheaper for labs. They are also focused on increasing the multiplex capability of PCR reactions, which will allow labs to test for more targets in a single reaction. Dr. Sharma and Dr. Carpenter also discuss their leadership styles and offer advice on being reliable, thinking about the application of science, and staying creative. They express concern about the growing distrust of science and the spread of misinformation, particularly in the age of social media. What excites them most is the opportunity to solve scientific challenges and create products that have a societal impact.
We're SO hyped to share the trailer for Help This Garden Grow, the second Respair project dropping this summer. It's dropping 7/27, and we're celebrating with a BIG release party at the Winter Garden in the Harold Washington Library. It's free and open to the public, come through! Here's the RSVP link: Help This Garden Grow is a new podcast docuseries telling the story of Hazel Johnson, a visionary of the Environmental Justice movement and a resident of the Altgeld Gardens community on the far South Side of Chicago. Hazel is the founder of People for Community Recovery, a 40 year-old organization that fights to address the toxic industrial pollution that has been killing the members of her community. Over the course of the multigenerational multipart documentary, we talk with organizers, policy-makers, historians, and community members about how PCR emerged and led, the legacy of Ms. Johnson's work, and how this marginalized Chicago pocket built the lineage of today's vibrant, impactful, and necessary modern environmental justice movement. Help This Garden Grow is presented by Respair Production & Media, Elevate, and People for Community Recovery.
According to the World Economic Forum, between 75 and 199 million tons of plastic waste are floating in and polluting the world's oceans. The 5 Gyres Institute reports that the volume of plastic entering the seas doubles every six years. There are genuine efforts to develop circular, sustainable packaging amid waves of greenwashing claims. Meet Vanessa Coleman, CEO of Oceanworks, which collects ocean plastics for recycling that it sells to companies committed to using post-consumer recycled, or PCR, plastics in new products and packaging. Oceanworks has developed a network of partners that collect and recycle plastics found on beaches and in waterways around the world, which the Oceanworks Guaranteed label can identify — these programs' environmental, social, and recycling practices are reviewed regularly. Oceanworks can provide end-to-end audits of its plastics supply chain to inform packaging designers about where the materials they choose are collected, processed, and remanufactured.Oceanworks Guaranteed® certified recycled plastics are used in Glad to be Green products, Sperry Seacycled sneakers, Delta Faucets' Ocean Plastic Shower Head, and many other products. While shoppers can browse these products at Oceanworks' website, the real action happens in the company's online materials catalog. It sells recycled PET (#1), HDPE (#2), and Polypropylene (#5) plastics, as well as recycled yarns and fabrics, bottles, and zippers made from ocean plastics. Product designers and the teams responsible for packaging get access to a wide range of materials that contribute to a cleaner world as long as they continue to be recycled responsibly. We discuss the National Strategy to Prevent Plastic Pollution, the potential for “advanced recycling” technologies that promise to make plastic as recyclable as metals, and the environmental and recycling impacts of plastics and the additives they contain.You can learn more about Oceanworks at https://oceanworks.co/
This episode... More evidence to support the use of neoadjuvant ICI/chemo in stage III NSCLC to obtain pCR published this week with NADIM II. Time to rethink giving ICI/TKI combination therapy to favorable-risk metastatic RCC patients? (Finally, I'm not the only one saying this anymore.) NADIM II: https://www.nejm.org/doi/full/10.1056/NEJMoa2215530 FDA Pooled Analysis Favorable Risk metastatic RCC: https://doi.org/10.1016/j.eururo.2023.05.030
Neste episódio falarei sobre os principais exames de sangue para pesquisarmos inflamação. Quais são os marcadores inflamatórios? Quais são dos valores aceitos? Quais os valores eu pratico? Como saber se estou inflamado? O que é PCR (proteina C reativa) ? O que é VHS?
In June 1991, The New York Times published a piece titled “Scientists Study Ancient DNA for Glimpses of Past Worlds.” Published a year after Michael Crichton's 1990 novel Jurassic Park, on which the 1993 blockbuster would be based, the article opens “Will it one day become possible to breed a living dinosaur from genes preserved in fossils?” More than 30 years on, we obviously have not bred a living dinosaur, nor come even close. But the early 1990's kicked off the first age of ancient DNA with massive optimism, stimulated by the spread of polymerase chain reaction (PCR) technology, which allowed the amplification of minute amounts of genetic material. I remember this particular article because an extract was passed around my 8th-grade science class. Today I talk to Dr. Elizabeth Jones, author of Ancient DNA: The Making of a Celebrity Science, about the excitement in paleogenetics in the 1990s, its subsequent retrenchment as a field, and the prompt renaissance in the late 2000's under the leadership of Svante Pääbo and Eske Willerslev. Jones first articulates her idea of what “celebrity science” is. Rather than science being driven by an individual, like Albert Einstein or James Watson, she argues that fields of science itself can become a celebrity due to strong public interest. This was clearly true in the 1990's, with the frequent popular press stories about dinosaur DNA and the tie-in to Jurassic Park, and in the late 2000's and down to the present, culminating in Pääbo being awarded a Nobel Prize. In her book, Jones views celebrity science as a wholly positive development, allowing for a full exploration of the possibilities of a field, and putting the spotlight on possible problems so that science's self-correction mechanisms can kick-in. This was certainly true with the first “hype cycle” of ancient DNA, when it turned out that many of the specific results were actually the result of modern contamination. Jones outlines how in fact it was Pääbo and his collaborators who were the skeptics demanding stricter methods and frameworks before publication. Ancient DNA then recounts how a second hype cycle was triggered by genomic sequencing's integration into paleogenetics, opening up an avenue to obtain the whole genomes of Neanderthals and other species. Jones' Ph.D. work, which led to Ancient DNA, was just concluded in 2015. But she recalls the mad last-second scramble to update the manuscript at the last second because of this last half a decade's flood of results. They consider the field's future possibilities, and finally the prospects for genuine retrieval of biological material from actual dinosaurs, the original ambition in the 1990's
Drs. Vamsi Velcheti and Jack West discuss ADAURA, KEYNOTE-671, and KEYNOTE-789 trials in NSCLC and the first pivotal study of sunvozertinib for the treatment of NSCLC with EGFR exon 20 insertion mutations. TRANSCRIPT Dr. Vamsi Velcheti: Hello, I'm Dr. Vamsi Velcheti, your guest host for the ASCO Daily News Podcast. I'm a professor of medicine and director of thoracic medical oncology at the Perlmutter Cancer Center at NYU Langone Health. My guest today is Dr. Jack West, a thoracic oncologist and associate professor in medical oncology at City of Hope Comprehensive Cancer Center. Today, we'll be discussing practice-changing studies and other key advances in lung cancer that were featured at the 2023 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode and disclosures of all guests on the ASCO Daily News podcast are available at asco.org/DNpod. Jack, there was a lot of exciting new data that emerged from the ASCO Annual Meeting, and it's great to have you back on our podcast today to talk about all the key updates in lung cancer. Dr. Jack West: Absolutely. Thanks so much. It's always a high-energy meeting, and there was a lot to talk about in the lung cancer sessions this year for sure. Dr. Vamsi Velcheti: Let's begin with LBA3, the ADAURA trial. This was presented in the Plenary Session at ASCO; we've heard previously the DFS updates from previous meetings, and overall survival updates were presented at the ASCO 2023 Annual Meeting. So, Jack, what was the highlight of the presentation for you? And could you put things in context for us? We have known about the DFS data for a while now. What gets you so excited about this study? Dr. Jack West: Well, we've actually been focused on this trial for literally 3 years, since Dr. Herbst presented it at another Plenary presentation back in the ASCO Meeting in 2020 when we saw tremendous differences in the DFS data. Again, this was a trial of patients with resected stage 1b to 3a EGFR mutation-positive non-small cell lung cancer. Nearly 700 patients were randomized to after-surgery, and for many, but not all, patients undergoing chemotherapy, it wasn't mandated. But after that, they were randomized to get adjuvant, placebo, or osimertinib for up to 3 years. And we saw huge differences in the disease-free survival from the first presentation, with a hazard ratio in the range of 0.2. We have notably seen significant improvements in disease-free survival before with other EGFR TKIs for this population after surgery, but nothing in this range. And it's also notable that in the various other trials of other EGFR inhibitors in the postoperative setting, we've seen a DFS benefit, but that didn't translate to an improvement in overall survival. So, seeing a press release that this was associated with a significant and, in fact, highly significant by report, improvement in overall survival, as well as DFS, was really notable. What's also, I think, particularly important as a focus of this is that in the later presentations of this work, with longer follow-up last year, we saw that the DFS curves showed a drop in the DFS starting after these patients had completed 3 years of treatment. So, really suggesting that at least some, if not many or most of these patients who had been on adjuvant osimertinib were subject to a higher risk of relapse once they completed that. So, again, making the endpoint of overall survival particularly important. It's always been to me the endpoint we should care about most in a curative setting. Although the DFS was the primary endpoint of the study and it was powered and built around specifically focusing on the DFS difference, so overall survival was reassuring, I think, when we actually saw it, but not what the trial was centered around. And what we saw was a very dramatic improvement in overall survival with a hazard ratio of 0.49. That was essentially the same for the patients with stage 2 to 3a disease, as well as the broader population with stage 1b to 3a disease. When we look at the absolute numbers for overall survival at 5 years, there was an improvement from 73% to 85% with osimertinib, and in the population from 1b to 3a, an improvement from 78% to 88%. So, many things to comment on here. Really remarkable to see an 88% 5-year survival in the osimertinib arm that includes patients with stage 3a disease. I would say that there's still some controversy, some questions about this, and it really centers around a few things. One is, like many global trials, this one enrolled patients from many places that did not have the same standard of care staging that we follow in the U.S. There wasn't any specification or mandate for PET scans, which would be very routine in the U.S. And brain MRIs were not mandated either. And so there were almost certainly some patients with more advanced disease that was not detected that would be a big advantage for the osimertinib arm, but really not characterized. And also, the crossover was made possible to osimertinib starting in April of 2020, but only 38.5% of the patients on the control arm actually received osimertinib at the time of relapse. And even though many of the other patients who had a relapse did get another EGFR inhibitor, I don't think there's much question that osimertinib is the preferred and optimal EGFR TKI. And so there were a couple of important factors kind of going for this trial. One is the long, long, long duration of treatment at 3 years, though with a drop-off, I think some questions about whether even that is enough, and we might be tempted to treat beyond 3 years. And then how much did the inability of most of the patients on the control arm to get osimertinib later contribute? My personal view is that it is a troubling aspect of this trial. But also so many other trials that they're run globally in places where we arguably perpetuate these disparities by running these trials that, in part, magnify the differences between the two arms because some patients just will not have access to what is our best standard of care in the U.S., or many other parts of the world, but weren't necessarily available to many of the patients on the control arm where it was conducted. So, I think that's always a concern. It's definitely an issue of this trial, but I would not say it's unique to this one. Dr. Vamsi Velcheti: Very good points, Jack, and I completely agree with you. I think those certainly are concerns. But on the other hand, this is a pragmatic trial and that's the real-world scenario in terms of access issues, in terms of osimertinib globally, correct, in the stage 4 setting, even though we all agree that osimertinib is the best option for patients with metastatic EGFR-mutated lung cancer, I think that's obviously a reflection of global access issues and global disparities and changes in standard of care in terms of workup as well. So, it's somewhat of a pragmatic trial in some ways and I completely agree with you, I think that may have potentially had some impact on the overall survival. Dr. Jack West: Well, I would clarify that I don't think that this really highly significant difference in overall survival is undermined completely by this. There's no question in my mind that with the huge difference in disease-free survival that we'd already seen for 3 years, it has become our standard of care really for this population at least to offer it, if not to strongly recommend it. But I would say that most of us have been quite inclined to recommend it, perhaps with caveats. And I would say that this overall survival benefit mostly corroborates that, even if there are some concerns about how these trials are done, but it's still an impressive difference that would lead me to only cement my practice of pursuing it in this setting. I just would love to re-examine how we conduct these trials and potentially potentiate disparities that exist and don't want to have our trials be more positive by capitalizing on that. Dr. Vamsi Velcheti: Let's move on to the next abstract, LBA100; this is the KEYNOTE-671 trial. This was featured during the meeting's Clinical Science Symposium. This is a study of pembrolizumab or placebo plus platinum doublet followed by surgical resection and pembrolizumab or placebo for early-stage non-small cell lung cancer. Jack, what was the key message from this trial, and do you consider this as practice-changing? Dr. Jack West: This has been an area where we've seen really dramatic evolution in our practice patterns, specifically, at least for patients who don't have a tumor harboring an EGFR mutation or ALK rearrangement. I would say that there has been some momentum toward preoperative neoadjuvant therapy, specifically based on the CheckMate-816 trial that gave chemo with nivolumab versus placebo and showed a significant improvement in the pathologic complete response rate at surgery as well as event-free survival. The overall survival looks encouraging but is still early and hasn't met the threshold for statistical significance, and that's FDA-approved. But we still question whether there's a value to doing anything in the postoperative setting. And the CheckMate-816 trial did not include that as part of the trial. It allowed postoperative management at the judgment of the treating physician but didn't really prescribe anything. We now have the results of several trials in the last few months that have added a component in the postoperative setting in addition to three or four cycles of preoperative chemoimmunotherapy. And the first one that gave us a glimpse was the AEGEAN trial presented by Dr. John Heymach at AACR in April of this year that looked at chemo and durvalumab versus chemo placebo and then followed by a year of durvalumab versus placebo after surgery. That showed results in terms of major pathologic response and event-free survival that are significantly better with immunotherapy. Not clearly superior to what we would see with CheckMate-816. And then even more recently, we saw a monthly Plenary presentation from ASCO with the Neotorch trial presented by Dr. Shun Lu of China. This was a Chinese trial only that presented results just for patients with stage 3 disease thus far. This included patients with stage 2 or stage 3, but what we saw is stage 3 results and that looked at chemo with toripalimab for 3 cycles versus placebo and then a year of checkpoint inhibitor or placebo. This also shows a benefit with the addition of immunotherapy, but not clear if that's better than what we can already achieve with neoadjuvant alone with the Checkmate-816 approach. And then what we have now is a presentation and simultaneous publication by Dr. Heather Wakelee of KEYNOTE-671. And this is really almost the exact same trial design as AEGEAN. It's 4 cycles of platinum doublet chemotherapy and it is for patients with stage 2 to 3a disease. And this gave 4 cycles of chemotherapy with placebo or pembrolizumab. And then after surgery, patients would go on in the investigation arm to a year of pembrolizumab or to the additional year with placebo. And this shows a significant improvement in event-free survival with a hazard ratio of 0.58. It's most prominent in patients with high PD-L1, where the hazard ratio is 0.42. But there's still a benefit in patients with PD-L1 less than 1%, where it's 0.77. And there was a trend toward better overall survival here, hazard ratio of 0.73. It does not reach statistical significance at this early point. It's still preliminary but certainly looks encouraging. And there are also significant improvements in major pathologic response, where less than 10%, about a threefold difference from 30.2% with immunotherapy compared to 11% with placebo. And a very impressive improvement in pCR rate, which is 18.1% with the chemo and pembro compared to 4% with chemotherapy alone. Not surprisingly, when we look at event-free survival, it's best in the patients who achieve a pathologic complete response, but pembrolizumab improved outcomes in event-free survival even for those who didn't achieve a pCR. The real question I would say is does the addition of a year of checkpoint inhibitor therapy postoperatively add to what we already achieve with those first three cycles with chemo-neo or 4 cycles with maybe one of these other options? And these trials can't answer that question because they just include them as a package deal. There's no way to tease apart right now the component of what incremental benefits you get from that. And it certainly adds a year of time coming in for every 3-week infusions. Even if you space that out, it's still a year of coming in and getting infusions, potential cumulative immune-related toxicities, and a lot of cost versus potentially being done. And I think that really is the big question at this point of do you want to recommend something when we don't really have a precedent for much benefit beyond the first 4 cycles? Perhaps. Certainly, we give maintenance pemetrexed and other immunotherapies and there can be benefit there. So, I wouldn't say you necessarily cap that. But if there is resistant disease after the first 4 cycles you've already given 3 cycles, how much benefit is there? How likely is it that you're going to eradicate the last cancer cells with more? That said, I think many patients, and oncologists myself perhaps included, are going to be inclined to err on the side of possibly over-treating, but at least trying to give everything that is part of a widely studied, FDA-approved approach once these options become available. I just think it's going to end up as a careful discussion with each patient about whether they'd prefer to just say they're done or do that extra year and really feel that even if it comes back, they've done everything that made sense to try. Dr. Vamsi Velcheti: Very good points, Jack. So let's move on to another abstract, which is the LBA9000. This is the KEYNOTE-789 trial. In my opinion, this is the most important negative phase 3 trial in lung cancer in a while. This is a trial looking at pemetrexed platinum with or without pembrolizumab in patients who have EGFR mutation-positive metastatic non-small cell lung cancer. So, what are your key takeaways, Jack? Dr. Jack West: Well, I would say essentially we've been waiting to figure out what is the best treatment approach for patients with acquired resistance after osimertinib. And most of the patients had received osimertinib for their EGFR mutation-positive non-small cell. This is essentially KEYNOTE-189 being run in the EGFR mutation-positive patients after they've exhausted at least the major benefit of EGFR TKI therapy. What we saw was a hazard ratio for progression-free survival of 0.8. It didn't quite make it across the threshold for efficacy, a significant difference. And so it missed that efficacy boundary. And overall survival, the hazard ratio is 0.84, also missing the efficacy boundary. When you look at the actual curves, they show modest separation, nothing eye-popping, certainly compared to some of the other trials we're talking about. But I wouldn't say they show no benefit. And I think that's, to me, why there's really still a role for a nuanced thought process and maybe some discussion about how negative this is. This is not, in my mind, stone-cold negative with no patients benefiting from immunotherapy. This is a trial that really suggests that there's a subset of patients who are benefiting from immunotherapy. And we've also seen going back to subset analysis of the IMpower150 trial and also the ORIENT-31 trial with sintilimab and a bevacizumab biosimilar, another anti-VEGF inhibitor. These trials both really indicated a benefit in this population after EGFR TKI therapy of immunotherapy combined with VEGF. I think there could still be a value in there. I don't want to be a Pollyanna or too open-minded, but I think that there was at least a suggestion that this could still be a fruitful avenue. I think that this is still something we should do additional studies on that could bear fruit. I wouldn't close the door and categorically say this is just never going to translate to any benefit for any of these patients. Dr. Vamsi Velcheti: The key thing, though, is, like in EGFR mutant patients I think in the previous studies as well, the response rates with single-agent PD-1 have been very minimal. And I think one of the things that's actually very important to highlight is in the operative setting, the early-stage setting, unfortunately, some of the trials with immunotherapy have included patients with an EGFR mutation. And now we have a treatment option for those patients within the adjuvant setting, especially osimertinib. We just heard from the ADAURA trial, which has a clear significant overall survival benefit. So I think it's really important to test for EGFR mutation in all stages. And if somebody with the early stage has an EGFR mutation, adjuvant immunotherapy, or perioperative immunotherapy may not be the best option for those patients. Dr. Jack West: Right. I agree with that, although it is interesting that the KEYNOTE-671 trial did have some small population of patients with an EGFR mutation, and in that subset analysis, they seem to benefit from the pembrolizumab. I would not say that we should divert from ADAURA, but I'm just not as sure that our previous statement and mindset that immunotherapy just categorically doesn't work for patients with driver mutations is that simple. First of all, there is some heterogeneity about which driver mutation, and the ALK-positive patients seem to really get no benefit. But I think there's still some questions about immunotherapy for EGFR. Certainly, patients with KRAS or BRAF V600E seem to benefit like the broader range of patients. And I would also say maybe it's different whether you're giving immunotherapy combined with chemotherapy versus as monotherapy. So that's why I'm just not that sure we really can characterize this that well yet. The one additional point I would make about KEYNOTE-789 and the potential role of immunotherapy is that some experts in thoracic oncology and general oncologists alike may prefer to introduce chemotherapy at a time of progression, but keep the osimertinib going, maybe particularly for patients with brain metastases, whether current or a history of them, where we really feel that the osimertinib adds a critical component to CNS control. We don't want to ever give osimertinib or probably other EGFR TKIs concurrently with immunotherapy. So that's just a factor that we'd really want to consider when we're prioritizing where to fit in immunotherapy, if at all. Dr. Vamsi Velcheti: Thank you, Jack. And let's move on to the next abstract, Abstract 9002. This is a pivotal study of results from the sunvozertinib, which is an EGFR exon 20 insertion site mutation drug. There's some very promising data. Jack, how do you feel this study is going to influence practice? Dr. Jack West: Well, this is not an agent we have access to broadly yet, but I was quite impressed by it overall. I didn't mention it. We talked about it in the pre-ASCO discussion, and it was really one that I would mark as potentially practice-changing when we can get it. DZD 9008 or sunvozertinib is a potent inhibitor of exon 20 insertion mutations, and this was 97 patients, and the majority had had a couple of lines of prior therapy. They had to have gotten chemo, and the response rate was 60%, and it was really comparable efficacy with the different mutation subtypes. I think that the main thing that I would want to clarify a little better in my own patient population is how well the drug is really tolerated. We talked about that there was not really much grade 3 toxicity and that's true, but diarrhea rates were 67%, even though it was grade 3 and just about 8%. But grade 2 diarrhea or grade 2 rash in patients who are on this therapy, we hope for a long time, I think is something we shouldn't minimize. And I think that particularly our mindset about toxicity needs to be different when we're talking about giving a treatment for 2 or 4 cycles and then being done with it versus something we hope we're going to be giving longitudinally. And we really don't want to minimize the potential impact on the quality of life of patients who are experiencing grade 2 rash, diarrhea, or paronychia for months and months, maybe more than a year at a time. But that said, this is twice the response rate if not more than that of what we have already had for patients with this molecular aberration with an exon 20 insertion. So I think it's compelling and I think that it's going to be really valuable to offer to our patients. I just would like to clarify better how well patients who are actually on it are feeling when you incorporate the potentially chronic toxicity issues. Dr. Vamsi Velcheti: Thank you, Jack. And let's move on to the last abstract. This the LUNAR study, LBA9005. This is a positive phase 3 study that looked at tumor-treating fields or TTF therapy with standard of care treatments in metastatic non-small-cell lung cancer following platinum failure. This has been talked about a lot at ASCO, and Jack I'm eager to hear your key takeaways about this study. Dr. Jack West: Well, we knew from a press release several months ago, I think back in February, that there was a significant improvement in overall survival with the addition of tumor-treated fields. Again, this concept that electric fields can lead to antimitotic effect and potentially downstream induction of immunogenic cell death and enhanced immune response, that's at least the concept. And it's of course established, has utility in patients with glioblastoma, although kind of, I would say underutilized because it can be cumbersome. And I think that's one of the things we need to factor in is that this is not the easiest approach to pursue. But we don't have that many therapies that improve overall survival significantly in previously treated patients with non-small cell lung cancer. So, I think there's good reason to focus on this and ask how beneficial it is. It was notable, it was pretty much an even split of patients enrolled on the trial, 276 patients total, but about half had gotten chemo but not gotten immunotherapy before. And then the other half, I would say the clear majority, had gotten immunotherapy as well as chemo and got docetaxel-based treatment. And the overall survival benefit was significant for the intent to treat total population with a hazard ratio of 0.74 and a difference in 3-year survival of 18% favoring the addition of tumor-treating fields on the chest versus 7% in the patients who didn't. It really seemed to separate between the patients who had not had an immune checkpoint inhibitor and got tumor-treating fields with the checkpoint inhibitor where the hazard ratio is 0.63 and those who got tumor-treating fields with docetaxel where the hazard ratio was 0.81. So it really wasn't significant in this population. Toxicity, no real surprises compared to what we already knew about tumor-treating fields. Mostly dermatitis, but I would say that one of the kind of unmeasured issues is that this is a device that people have to wear on their chest carrying a battery pack with them all day long. It's essentially all the waking day, and so I think that's at least cumbersome. I wouldn't call it prohibitive, but it's a challenge. And I think we need to really ask whether the juice is worth the squeeze, whether the benefit is that compelling. And I question that when we're talking about an agent that doesn't significantly move the needle against docetaxel alone. Again, this is a population where in the U.S. we have ramucirumab to add to docetaxel. Not everyone does that. It's not uniform, but that has a statistically significant, though modest survival benefit associated with that. We don't do better than that with tumor treating fields. And so, I think that this is an option that merits discussion and some patients may opt for it, but I suspect that most of my patients would not find the absolute difference to be that compelling for the challenges it incurs. I don't know what your perspective is here. Dr. Vamsi Velcheti: I completely agree, Jack. And I think the study design and just the fact that the standard of care has changed over the last 5, actually 6 years since the study has been open. And I'm not really so sure I could really make much sense of the data in terms of the standard of care combination with TTF providing more benefit. And I think there are more questions than answers here and I'm not so sure which populations would benefit the most. And I think, I hate to say this, but this is a nice proof of concept. I hate to say this because it's a phase 3 study and it's a positive phase 3 study, but it's clinical relevance with the current standard of care, I think, I'm not really sure how much of an impact this would really have. Well, Jack, I've really enjoyed speaking with you about these key advances in lung cancer that were featured at the 2023 ASCO Annual Meeting. Our listeners will find links to all the studies discussed today in the transcript of this episode. Thank you so much, Jack, for joining us today. Dr. Jack West: Always a pleasure. Thanks so much. Dr. Vamsi Velcheti: And just like that, we've reached the end of another enriching episode. But remember, like all good things, this too must come to an end, but only until we meet again. We really would like your feedback on the podcast. If you enjoyed the podcast, please rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Vamsidhar Velcheti @VamsiVelcheti Dr. H. Jack West @JackWestMD Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Vamsidhar Velcheti: Honoraria: ITeos Therapeutics Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen, Elevation Oncology, Taiho Oncology, Merus Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline Dr. Jack West: Honoraria: AstraZeneca, Genentech/Roche, Merck, Takeda, Mirati, Regneron, Amgen, Abbvie Consulting or Advisory Role: AstraZeneca, Genentech/Roche, Merck, Takeda, Mirati Therapeutics, Regneron, Amgen, Abbvie, Summit Therapeutics Speakers' Bureau: Takeda, Merck, AstraZeneca
Fauci's First murders? HIV-AIDS - Ken McCarthy, Author of Fauci's First Fraud joins us. In my judgment, investigative writer Ken McCarthy's new book, Fauci's First Fraud proves that Tony Fauci's first wave of killing people wasn't with Covid, it was with the HIV/AIDS events. The book also demonstrates that Fauci used the identical pattern in his attack against same-sex attracted men as he has used against all of society. When men from highly-sexualized, same-sex communities made themselves very sick by constant partying, indiscriminate sex strangers, ma